Tasfygo (Tasurgratinib Succinate)

Tasfygo (tasurgratinib succinate) is a fibroblast growth factor receptor (FGFR) selective tyrosine kinase inhibitor indicated for the treatment of patients with unresectable biliary tract cancer with FGFR2 gene fusions or rearrangements that progressed after cancer chemotherapy.

It is a prescription anticancer medicine and must be used under the supervision of a qualified oncologist.

Recommended Dosage:
The recommended adult dose of Tasfygo is 140 mg (four 35 mg tablets) taken orally once daily under fasting conditions. The dose may be reduced as appropriate according to the patient’s condition.

Tablets should be taken as directed by the treating physician. If a dose is missed, patients should follow their oncologist’s instructions and should not take a double dose to make up for a missed one. Because Tasfygo is taken under fasting conditions, patients should follow guidance on timing relative to meals carefully.

• Treatment with Tasfygo may increase blood phosphate levels because of FGFR inhibition. Regular blood monitoring is required during treatment. If phosphate levels increase, dietary modifications, phosphate-lowering therapy, dose interruption, or dose reduction may be required.
• This therapeutic drug may cause retinal detachment and other eye disorders that can affect vision. Patients should undergo regular ophthalmologic examinations and immediately report eye pain, blurred vision, visual disturbances, or sudden changes in eyesight during treatment.
• Eye-related side effects such as dry eyes, keratitis, and corneal abnormalities have been reported with Tasfygo therapy. Routine eye monitoring is required, and immediate medical evaluation should be considered if any new or worsening eye symptoms occur.
• This medicine may cause redness, pain, peeling, swelling, or discomfort on the palms of the hands and soles of the feet. Early recognition and supportive care are required to reduce symptoms and maintain treatment continuity.
• Treatment with Tasfygo tablets may result in nail-related complications, including nail inflammation, discoloration, brittleness, or infection around the nails. Patients should monitor nail health and inform their clinician in case signs and symptoms become serious or persistent.
• Elevated liver enzymes and abnormal liver function tests have been observed during Tasfygo treatment. Regular liver function monitoring is required, particularly in those with ongoing liver disease, to identify and manage potential liver-related complications immediately.
• As per the mechanism of action, Tasfygo may cause harm to an unborn baby. Women who are pregnant or planning pregnancy should discuss potential risks with their healthcare professional before starting treatment

What documents are required to import TASFYGO to India?

TASFYGO (tasurgratinib succinate) may be imported in the patient’s name only, by patients or government hospitals. The following documentation is required:

• A valid prescription from a qualified doctor
• The patient’s diagnostic reports
• Patient ID proof (issued by the Government of India)

How is the order confirmed?

The order is confirmed only after receipt and verification of a valid prescription from the doctor and an import permit, if applicable.

Is TASFYGO available in India?

TASFYGO (tasurgratinib succinate tablets) is a prescription medicine that legally requires a doctor’s prescription to be dispensed. As of current publicly available information, TASFYGO is not commercially marketed in India.

However, patients in India can legally access TASFYGO through the Named Patient Program (NPP) — an import provision that allows a medicine not yet registered in India to be imported in the name of an individual patient, on the prescription of their treating physician.

Indian Pharma Network (IPN) acts as a facilitator under named patient supply, providing input on:

• Availability of Tasfygo in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Pune, etc.) and pathways to access it
• Availability in Gulf countries (Bahrain, Oman, Qatar, Kuwait, Iraq, Saudi Arabia, and the UAE).
• Tasfygo price in India under the NPP route
• Sourcing from genuine, reliable channels in the USA, Canada, Europe, and Australia 
• Ensuring full transparency throughout the process

TASFYGO can be made available to patients, doctors, and hospitals in Gurgaon, Delhi, Bangalore, Mumbai, Navi Mumbai, Thane, Hyderabad, Mysore, Kerala, Chennai, Coimbatore, Madurai, Kolkata, Ahmedabad, Surat, Vadodara, Pune, Nagpur, Nashik, Jaipur, Udaipur, Lucknow, Kanpur, Gorakhpur, Chandigarh, Mohali, Faridabad, Noida, Ghaziabad, Kochi, Trivandrum, Kozhikode, Thrissur, Kannur, Mangalore, Bhubaneswar, Patna, Ranchi, Raipur, Guwahati, Visakhapatnam, Vijayawada, Goa, Jammu, Srinagar, Dehradun, Bhopal, Indore, Ludhiana, Amritsar, and others— and can facilitate delivery to the patient’s treating hospital. Orders are confirmed only after receipt of a valid doctor’s prescription and an import permit, where applicable.

Indian Pharma Network (IPN) can source TASFYGO from reliable channels across the world and facilitate supply to patients, doctors, and hospitals, offering worldwide access to this treatment under applicable legal provisions. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the patient’s address from New Delhi, India, after legal requirements are fulfilled.

For Tasfygo cost in India and availability, contact IPN at WhatsApp: +91 98104 69557 | Toll-Free: 1800-1200-365 or email info@indianpharmanetwork.in.

What is the generic name for the brand drug Tasfygo?

Tasurgratinib succinate is the generic name for the brand drug Tasfygo.

What condition does Tasfygo treat?

Tasfygo (tasurgratinib) treats unresectable biliary tract cancer (bile duct cancer) with FGFR2 gene fusions or rearrangements that have progressed after chemotherapy. It is an FGFR-targeted anticancer therapy.

Who manufactures Tasfygo?

Tasfygo is manufactured by Eisai Co., Ltd., which discovered the compound in-house at its Tsukuba Research Laboratories.

Is Tasfygo approved by the FDA?

As of current publicly available information, Tasfygo has not been approved by the US FDA. Its first approval was in Japan in September 2024.

Where is Tasfygo approved?

Tasfygo received its first approval in Japan on September 24, 2024, where it also holds orphan drug designation. It is not yet widely approved in other countries.

What strength and dosage form is available?

Tasfygo is available as 35 mg tasurgratinib succinate tablets. The usual adult dose is 140 mg (four tablets) once daily under fasting conditions.

How is Tasfygo taken?

Tasfygo is taken orally once daily under fasting conditions, at the dose prescribed by the treating oncologist. The dose may be reduced based on the patient’s condition.

What are the most common side effects of Tasfygo?

The most commonly reported side effects are nausea, fatigue, dry eyes, blurred vision, nail disorders, skin reactions (including paronychia), increased creatinine levels, proteinuria, joint pain, hyperphosphatemia, hand-foot syndrome, diarrhea, elevated liver enzymes, and stomatitis.

How does Tasfygo import in India work?

Tasfygo import in India is possible through the Named Patient Program (NPP) — on behalf of an individual patient with a valid doctor’s prescription. Indian Pharma Network (IPN) helps manage the process, including documentation, approvals, and delivery, so the medicine reaches the patient safely and legally.

Who is a reliable Tasfygo supplier in India?

Indian Pharma Network (IPN) facilitates compliant access to Tasfygo in India through global sourcing channels and structured documentation support for eligible patients in accordance with applicable regulatory provisions.

How much does Tasfygo cost in India?

Tasfygo is not yet approved or marketed in India, but patients can legally access it through the Named Patient Program. Prices may vary over time due to market and regulatory factors. For the latest Tasfygo cost in India, call +91 96548 60915 or WhatsApp +91 98104 69557 or email info@indianpharmanetwork.in.

Can Tasfygo be accessed in SAARC countries?

Yes. In addition to Gulf countries, Tasfygo can be accessed through import provisions such as the Named Patient Program in SAARC countries (India, Afghanistan, Maldives, Nepal, Bangladesh, Bhutan, Pakistan, and Sri Lanka). IPN can help facilitate compliant supply where permitted by local regulations.

Is it safe to buy Tasfygo® Tablets online in India?

Yes, one can buy Tasfygo in India from the Indian Pharma Network (IPN), as this medicinal product is not yet registered or available in the country. We can help facilitate the import of Tasfygo® tablets through legal channels.

Can Tasfygo be delivered to my treating hospital?

Yes. IPN can facilitate delivery of Tasfygo to the patient’s treating hospital across major Indian cities, under the Named Patient Program, with a valid doctor’s prescription and import permit where applicable. Leading hospitals include AIIMS Delhi, Sir Ganga Ram Hospital, Medanta – The Medicity, Apollo Hospitals Chennai, Christian Medical College (CMC), PGIMER, Kidwai Memorial Institute of Oncology, Adyar Cancer Institute, Amrita Hospital, Artemis Hospital, Safdarjung Hospital, Kauvery Hospital, Sri Ramachandra Medical Centre, Cytecare Cancer Hospital, MIOT International, SCTIMST, NIMS Hospital, KIMS Hospitals, AIG Hospitals, Bombay Hospital, Lilavati Hospital, Care Hospitals, Narayana Health City, Jaslok Hospital, Yashoda Hospitals, Fortis Memorial Research Institute, Kokilaben Dhirubhai Ambani Hospital, P. D. Hinduja Hospital, Manipal Hospitals, Aster Medcity, Indraprastha Apollo Hospital, King George’s Medical University (KGMU), Shalby Hospitals, Tata Memorial Centre, HCG Cancer Center, Basavatarakam Indo-American Cancer Hospital, Cancer Institute (WIA), Max Healthcare, and Rajiv Gandhi Cancer Institute & Research Centre.

What are the storage conditions for Tasfygo tablets?

Tasfygo® (tasurgratinib) tablets should be stored at room temperature, typically between 15°C and 30°C, protected from excessive moisture and kept in the original packaging